Carisma Therapeutics Inc.

Carisma Therapeutics Inc.

Biotechnology • Healthcare • Philadelphia, PA, United States • CARM (PNK)

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

267 491 6422 3675 Market Street, Philadelphia, PA 19104, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Carisma Therapeutics stock plunges after Nasdaq delisting notice - Investing.com
Investing.com • Oct 10
Carisma Announces Delisting from Nasdaq and SEC Deregistration - PR Newswire
PR Newswire • Dec 5
Philadelphia's Carisma Therapeutics winds down operations - The Business Journals
The Business Journals • Dec 16
Carisma Therapeutics, OrthoCellix enter definitive merger agreement - Yahoo Finance
Yahoo Finance • Jun 24
Carisma Therapeutics (CARM) to leave Nasdaq, deregister as it winds down operations - Stock Titan
Stock Titan • Dec 5

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Carisma Therapeutics Inc. had layoffs?
No layoff events have been recorded for Carisma Therapeutics Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Carisma Therapeutics Inc. have?
Carisma Therapeutics Inc. has approximately 46 employees.
What industry is Carisma Therapeutics Inc. in?
Carisma Therapeutics Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Carisma Therapeutics Inc. a publicly traded company?
Yes, Carisma Therapeutics Inc. is publicly traded under the ticker symbol CARM on the PNK. The company has a market capitalization of approximately $0.00 billion.
Where is Carisma Therapeutics Inc. headquartered?
Carisma Therapeutics Inc. is headquartered in Philadelphia, PA, United States at 3675 Market Street, Philadelphia, PA 19104, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.